货号:A102810 同义名: DFMO hydrochloride hydrate;MDL-71782 hydrochloride hydrate
Eflornithine HCl is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase, is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | decarboxylase ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eflornithine hydrochloride hydrate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Methyldopa | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Benserazide HCI | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Carbidopa |
+++
aromatic-L-amino-acid decarboxylase, IC50: 29 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Eflornithine hydrochloride hydrate is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. In subjects with excessive, unwanted facial hair, eflornithine 15% cream is superior to placebo in reducing hair growth. After 24 weeks' treatment, 58% of eflornithine and 34% of placebo subjects have at least some improvement in facial hirsutism[3]. The hair growth inhibitory activity of eflornithine was significantly enhanced when the eflornithine cream was applied onto a mouse skin area pretreated with microneedles. Cell proliferation in the skin and hair follicles was also significantly inhibited when the eflornithine cream was applied onto a skin area pretreated with microneedles[4]. Treatment of coarctation hypertensive rats with eflornithine resulted in a normalization of the contractile intensity to KCI and norepinephrine and relaxations to acetylcholine by 14 days of hypertension. Normalization of vascular function can occur in the presence of significantly elevated blood pressure upon chronic administration of eflornithine[5]. Male SD rats were administered single doses of racemic eflornithine hydrochloride as an oral solution (750, 1,500, 2,000, or 3,000 mg/kg of body weight) or intravenously (375 or 1,000 mg/kg of body weight). The mean bioavailabilities for L- and D-eflornithine were 41% and 62%, respectively, in the dose range of 750 to 2,000 mg/kg of body weight, with suggested increases to 47% and 83%, respectively, after a dose of 3,000 mg/kg of body weight[6]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
4.23mL 0.85mL 0.42mL |
21.13mL 4.23mL 2.11mL |
42.26mL 8.45mL 4.23mL |
CAS号 | 96020-91-6 |
分子式 | C6H15ClF2N2O3 |
分子量 | 236.645 |
别名 | DFMO hydrochloride hydrate;MDL-71782 hydrochloride hydrate;Eflornithine;DFMO;DL-α-Difluoromethylornithine (hydrochloride hydrate);Difluoromethylornithine hydrochloride hydrate;α-difluoromethylornithine hydrochloride hydrate;RMI-71782 hydrochloride hydrate |
运输 | 蓝冰 |
存储条件 |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
H2O: 85 mg/mL(359.19 mM),配合低频超声助溶 |
动物实验配方 |